1. Rare DEGS1 variant significantly alters de novo ceramide synthesis pathway.
- Author
-
Blackburn NB, Michael LF, Meikle PJ, Peralta JM, Mosior M, McAhren S, Bui HH, Bellinger MA, Giles C, Kumar S, Leandro AC, Almeida M, Weir JM, Mahaney MC, Dyer TD, Almasy L, VandeBerg JL, Williams-Blangero S, Glahn DC, Duggirala R, Kowala M, Blangero J, and Curran JE
- Subjects
- Blotting, Western, CRISPR-Cas Systems genetics, Ceramides metabolism, Female, Genotype, Hep G2 Cells, Humans, Male, Mexican Americans, Ceramides biosynthesis, Fatty Acid Desaturases genetics
- Abstract
The de novo ceramide synthesis pathway is essential to human biology and health, but genetic influences remain unexplored. The core function of this pathway is the generation of biologically active ceramide from its precursor, dihydroceramide. Dihydroceramides have diverse, often protective, biological roles; conversely, increased ceramide levels are biomarkers of complex disease. To explore the genetics of the ceramide synthesis pathway, we searched for deleterious nonsynonymous variants in the genomes of 1,020 Mexican Americans from extended pedigrees. We identified a Hispanic ancestry-specific rare functional variant, L175Q, in delta 4-desaturase, sphingolipid 1 (DEGS1), a key enzyme in the pathway that converts dihydroceramide to ceramide. This amino acid change was significantly associated with large increases in plasma dihydroceramides. Indexes of DEGS1 enzymatic activity were dramatically reduced in heterozygotes. CRISPR/Cas9 genome editing of HepG2 cells confirmed that the L175Q variant results in a partial loss of function for the DEGS1 enzyme. Understanding the biological role of DEGS1 variants, such as L175Q, in ceramide synthesis may improve the understanding of metabolic-related disorders and spur ongoing research of drug targets along this pathway., (Copyright © 2019 Blackburn et al.)
- Published
- 2019
- Full Text
- View/download PDF